Effects of troglitazone and metformin on glucose and lipid metabolism. Alterations of two distinct molecular pathways

James M. Lenhard, Steven A. Kliewer, Mark A. Paulik, Kelli D. Plunket, Jurgen M. Lehmann, James E. Weiel

Research output: Contribution to journalArticle

105 Citations (Scopus)

Abstract

Troglitazone and metformin are antidiabetic agents that belong to the thiazolidinedione and biguanide classes of drugs, respectively. To evaluate how these drugs influence fuel utilization, we compared their effects on several pathways regulating carbohydrate and lipid metabolism in vitro. Both drugs stimulated glucose transport and utilization in C3H10T1/2 cells, a cell line capable of differentiating into adipocytes when treated with thiazolidinediones. However, we observed that these drugs had a number of different in vitro effects. Unlike metformin, troglitazone stimulated β3-adrenergic receptor-mediated lipolysis, lipogenesis, and transcriptional activity of the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ). Further, by using a mitochondrial specific fluorescent dye, we found troglitazone to be more effective than metformin at increasing mitochondrial mass. In contrast to troglitazone, metformin was more effective at increasing mitochondrial fatty acid β-oxidation, peroxisomal fatty acid β-oxidation, and anaerobic respiration (i.e. lactate production). Additionally, metformin stimulated and troglitazone inhibited both aerobic respiration and basal lipolysis. Insulin enhanced the effects of troglitazone, but not those of metformin, on these cells. Taken together, the data show that troglitazone and metformin affect two distinct metabolic pathways: one that is anabolic (i.e. troglitazone) and the other that is catabolic (i.e. metformin). Further, these observations suggest that the metabolic activity of mitochondria may be lower in cells treated with troglitazone than with metformin.

Original languageEnglish (US)
Pages (from-to)801-808
Number of pages8
JournalBiochemical Pharmacology
Volume54
Issue number7
DOIs
StatePublished - Oct 1 1997

Fingerprint

troglitazone
Metformin
Lipid Metabolism
Glucose
Lipolysis
Pharmaceutical Preparations
Respiration
Fatty Acids
Biguanides
Thiazolidinediones
Oxidation
Lipogenesis
Peroxisome Proliferator-Activated Receptors
Mitochondria
Carbohydrate Metabolism
Cytoplasmic and Nuclear Receptors
Metabolic Networks and Pathways
Fluorescent Dyes

Keywords

  • Diabetes
  • Insulin
  • Metabolism
  • Metformin
  • PPARγ
  • Troglitazone

ASJC Scopus subject areas

  • Pharmacology

Cite this

Effects of troglitazone and metformin on glucose and lipid metabolism. Alterations of two distinct molecular pathways. / Lenhard, James M.; Kliewer, Steven A.; Paulik, Mark A.; Plunket, Kelli D.; Lehmann, Jurgen M.; Weiel, James E.

In: Biochemical Pharmacology, Vol. 54, No. 7, 01.10.1997, p. 801-808.

Research output: Contribution to journalArticle

Lenhard, James M. ; Kliewer, Steven A. ; Paulik, Mark A. ; Plunket, Kelli D. ; Lehmann, Jurgen M. ; Weiel, James E. / Effects of troglitazone and metformin on glucose and lipid metabolism. Alterations of two distinct molecular pathways. In: Biochemical Pharmacology. 1997 ; Vol. 54, No. 7. pp. 801-808.
@article{a6a4f18b9f07461cbea05c3383829d1b,
title = "Effects of troglitazone and metformin on glucose and lipid metabolism. Alterations of two distinct molecular pathways",
abstract = "Troglitazone and metformin are antidiabetic agents that belong to the thiazolidinedione and biguanide classes of drugs, respectively. To evaluate how these drugs influence fuel utilization, we compared their effects on several pathways regulating carbohydrate and lipid metabolism in vitro. Both drugs stimulated glucose transport and utilization in C3H10T1/2 cells, a cell line capable of differentiating into adipocytes when treated with thiazolidinediones. However, we observed that these drugs had a number of different in vitro effects. Unlike metformin, troglitazone stimulated β3-adrenergic receptor-mediated lipolysis, lipogenesis, and transcriptional activity of the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ). Further, by using a mitochondrial specific fluorescent dye, we found troglitazone to be more effective than metformin at increasing mitochondrial mass. In contrast to troglitazone, metformin was more effective at increasing mitochondrial fatty acid β-oxidation, peroxisomal fatty acid β-oxidation, and anaerobic respiration (i.e. lactate production). Additionally, metformin stimulated and troglitazone inhibited both aerobic respiration and basal lipolysis. Insulin enhanced the effects of troglitazone, but not those of metformin, on these cells. Taken together, the data show that troglitazone and metformin affect two distinct metabolic pathways: one that is anabolic (i.e. troglitazone) and the other that is catabolic (i.e. metformin). Further, these observations suggest that the metabolic activity of mitochondria may be lower in cells treated with troglitazone than with metformin.",
keywords = "Diabetes, Insulin, Metabolism, Metformin, PPARγ, Troglitazone",
author = "Lenhard, {James M.} and Kliewer, {Steven A.} and Paulik, {Mark A.} and Plunket, {Kelli D.} and Lehmann, {Jurgen M.} and Weiel, {James E.}",
year = "1997",
month = "10",
day = "1",
doi = "10.1016/S0006-2952(97)00229-3",
language = "English (US)",
volume = "54",
pages = "801--808",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "7",

}

TY - JOUR

T1 - Effects of troglitazone and metformin on glucose and lipid metabolism. Alterations of two distinct molecular pathways

AU - Lenhard, James M.

AU - Kliewer, Steven A.

AU - Paulik, Mark A.

AU - Plunket, Kelli D.

AU - Lehmann, Jurgen M.

AU - Weiel, James E.

PY - 1997/10/1

Y1 - 1997/10/1

N2 - Troglitazone and metformin are antidiabetic agents that belong to the thiazolidinedione and biguanide classes of drugs, respectively. To evaluate how these drugs influence fuel utilization, we compared their effects on several pathways regulating carbohydrate and lipid metabolism in vitro. Both drugs stimulated glucose transport and utilization in C3H10T1/2 cells, a cell line capable of differentiating into adipocytes when treated with thiazolidinediones. However, we observed that these drugs had a number of different in vitro effects. Unlike metformin, troglitazone stimulated β3-adrenergic receptor-mediated lipolysis, lipogenesis, and transcriptional activity of the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ). Further, by using a mitochondrial specific fluorescent dye, we found troglitazone to be more effective than metformin at increasing mitochondrial mass. In contrast to troglitazone, metformin was more effective at increasing mitochondrial fatty acid β-oxidation, peroxisomal fatty acid β-oxidation, and anaerobic respiration (i.e. lactate production). Additionally, metformin stimulated and troglitazone inhibited both aerobic respiration and basal lipolysis. Insulin enhanced the effects of troglitazone, but not those of metformin, on these cells. Taken together, the data show that troglitazone and metformin affect two distinct metabolic pathways: one that is anabolic (i.e. troglitazone) and the other that is catabolic (i.e. metformin). Further, these observations suggest that the metabolic activity of mitochondria may be lower in cells treated with troglitazone than with metformin.

AB - Troglitazone and metformin are antidiabetic agents that belong to the thiazolidinedione and biguanide classes of drugs, respectively. To evaluate how these drugs influence fuel utilization, we compared their effects on several pathways regulating carbohydrate and lipid metabolism in vitro. Both drugs stimulated glucose transport and utilization in C3H10T1/2 cells, a cell line capable of differentiating into adipocytes when treated with thiazolidinediones. However, we observed that these drugs had a number of different in vitro effects. Unlike metformin, troglitazone stimulated β3-adrenergic receptor-mediated lipolysis, lipogenesis, and transcriptional activity of the nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ). Further, by using a mitochondrial specific fluorescent dye, we found troglitazone to be more effective than metformin at increasing mitochondrial mass. In contrast to troglitazone, metformin was more effective at increasing mitochondrial fatty acid β-oxidation, peroxisomal fatty acid β-oxidation, and anaerobic respiration (i.e. lactate production). Additionally, metformin stimulated and troglitazone inhibited both aerobic respiration and basal lipolysis. Insulin enhanced the effects of troglitazone, but not those of metformin, on these cells. Taken together, the data show that troglitazone and metformin affect two distinct metabolic pathways: one that is anabolic (i.e. troglitazone) and the other that is catabolic (i.e. metformin). Further, these observations suggest that the metabolic activity of mitochondria may be lower in cells treated with troglitazone than with metformin.

KW - Diabetes

KW - Insulin

KW - Metabolism

KW - Metformin

KW - PPARγ

KW - Troglitazone

UR - http://www.scopus.com/inward/record.url?scp=0030773456&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0030773456&partnerID=8YFLogxK

U2 - 10.1016/S0006-2952(97)00229-3

DO - 10.1016/S0006-2952(97)00229-3

M3 - Article

C2 - 9353134

AN - SCOPUS:0030773456

VL - 54

SP - 801

EP - 808

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 7

ER -